Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G L Elfring

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancerR F DeVore, D H Johnson, J Crawford, et al.
The New England Journal of Medicine|September 28, 2000
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study GroupL B Saltz, J V Cox, C Blanke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 1998
Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumorsL B Saltz, D Spriggs, L J Schaaf, et al.
Cancer|March 26, 1999
A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinomaM L Rothenberg, J V Cox, R F DeVore, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1996
Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancerM L Rothenberg, J R Eckardt, J G Kuhn, et al.
The European Respiratory Journal|January 15, 2011
Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosisM Wilschanski, L L Miller, D Shoseyov, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 2, 2002
Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeksM L Rothenberg, J G Kuhn, L J Schaaf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 18, 1999
Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumorsR L Drengler, J G Kuhn, L J Schaaf, et al.
Transplantation Proceedings|September 1, 1978
The use of circulating rosette-forming cells as a guide to determination of ATG dose (dose-by-rosette)P E Byfield, C L Barth, J A Brodie, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 1999
Irinotecan therapy in adults with recurrent or progressive malignant gliomaH S Friedman, W P Petros, A H Friedman, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancerR F DeVore, D H Johnson, J Crawford, et al.
The New England Journal of Medicine|September 28, 2000
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study GroupL B Saltz, J V Cox, C Blanke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 1998
Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumorsL B Saltz, D Spriggs, L J Schaaf, et al.
Cancer|March 26, 1999
A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinomaM L Rothenberg, J V Cox, R F DeVore, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1996
Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancerM L Rothenberg, J R Eckardt, J G Kuhn, et al.
The European Respiratory Journal|January 15, 2011
Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosisM Wilschanski, L L Miller, D Shoseyov, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 2, 2002
Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeksM L Rothenberg, J G Kuhn, L J Schaaf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 18, 1999
Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumorsR L Drengler, J G Kuhn, L J Schaaf, et al.
Transplantation Proceedings|September 1, 1978
The use of circulating rosette-forming cells as a guide to determination of ATG dose (dose-by-rosette)P E Byfield, C L Barth, J A Brodie, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 1999
Irinotecan therapy in adults with recurrent or progressive malignant gliomaH S Friedman, W P Petros, A H Friedman, et al.
Pageof 2